Validation of an ELISA Synthetic Cannabinoids Urine Assay
| Autor: | Eliani Spinelli, Kevin L. Kleete, Sheena Young, Allan J. Barnes, Thomas M. Martin, Marilyn A. Huestis |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Pharmacology
Analyte Chromatography medicine.diagnostic_test Cannabinoids business.industry Metabolite medicine.medical_treatment Enzyme-Linked Immunosorbent Assay Urine Cross Reactions Article Medical services chemistry.chemical_compound chemistry Immunoassay Synthetic cannabinoids medicine Screening method Humans Pharmacology (medical) Reagent Kits Diagnostic Cannabinoid business medicine.drug |
| Zdroj: | Therapeutic Drug Monitoring. 37:661-669 |
| ISSN: | 0163-4356 |
| DOI: | 10.1097/ftd.0000000000000201 |
| Popis: | BACKGROUND Synthetic cannabinoids are touted as legal alternatives to cannabis, at least when first released, and routine urine cannabinoid screening methods do not detect these novel psychoactive substances. Synthetic cannabinoids are widely available, are a major public health and safety problem, and a difficult challenge for drug-testing laboratories. We evaluated performance of the National Medical Services (NMS) JWH-018 direct enzyme-linked immunosorbent assay (ELISA) kit to sensitively, selectively, and rapidly screen urinary synthetic cannabinoids. METHODS The NMS ELISA kit targeting the JWH-018 N-(5-hydroxypentyl) metabolite was used to screen 2492 urine samples with 5 and 10 mcg/L cutoffs. A fully validated liquid chromatography-tandem mass spectrometry method for 29 synthetic cannabinoids markers confirmed all presumptive positive and negative results. Performance challenges at ±25% and ±50% of cutoffs determined intraplate and interplate imprecision around proposed cutoffs. RESULTS The immunoassay was linear from 1 to 500 mcg/L with intraplate and interplate imprecision of ≤8.2% and |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|